Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients With Refractory Advanced Cancers
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-2322
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2005
Authors
Publisher
American Association for Cancer Research (AACR)